CME Hypertension Obesity 
Cardiometabolic Health Congress
NOVEMBER 14, 2024
cardiometabolic health CME/CE conference: the 19th Annual CMHC. 42% of adults are considered obese , increasing their risk of diabetes, hypertension, and cardiovascular issues. Additionally, 10% of the global population suffers from chronic kidney disease , with diabetes and hypertension as significant risk factors.
Cardiometabolic Health Congress
OCTOBER 25, 2024
The 19th Annual CMHC was more than just CME/CE medical education—it ignited global collaboration and inspired groundbreaking innovations. Attendees dove into cutting-edge topics, including FDA updates, resistant hypertension, and cardiac biomarkers. “I Aronne, MD , discussed advances in obesity pharmacology, while Virend K.
Cardiometabolic Health Congress
JULY 12, 2023
A vast collection of webinars, CME activities, expert interviews, on-demand event recordings, news articles, drug pipelines, and many other resources are now grouped into areas of specialty focus. For instance, a pediatric provider may be only interested in topics pertaining to childhood obesity.
Cardiometabolic Health Congress
FEBRUARY 23, 2024
Black History Month is a poignant backdrop to the alarming rise in obesity and type 2 diabetes, particularly among those of marginalized populations. Two major risk factors for CVD are hypertension and diabetes, which also place a heavier burden on minority groups.
Cardiometabolic Health Congress
JULY 25, 2024
Innovations in Cardiorenal Metabolic Medicine The event will focus on the whole spectrum of cardiorenal metabolic disease, including obesity, diabetes, lipids, hypertension, and cardiorenal disease. Michos, MD, MHS, FACC, FAHA, FASE, FASPC ; famed hypertension expert Keith C.
Cardiometabolic Health Congress
OCTOBER 30, 2024
This patient’s case presents a common and challenging scenario in primary care and endocrinology, where T2D, obesity, and metabolic dysfunction intersect with liver disease. Case Study: A Common Clinical Scenario This case study highlights the complex relationship between metabolic disease and liver health.
Cardiometabolic Health Congress
NOVEMBER 8, 2024
Healthcare professionals should consider pharmacotherapy options that address T2D, obesity, and liver disease: Statins : Statins are first-line therapies for managing dyslipidemia and reducing cardiovascular risk in patients with MASH. This dual action makes tirzepatide a promising option for treating MASH in patients with T2D and obesity.
Expert insights. Personalized for you.
96 
Let's personalize your content